

BACKGROUND

- > Major depressive disorder (MDD) is a com illness with nearly one in five people exper episode at some point in their lifetime
- Introduction of novel and efficacious agent treatment of depression has been relatively
- Psilocybin has become an agent of interest treatment of depression with recent studies supporting safety and efficacy

OBJECTIVE

- Examine the significance and potential of as an agent in the treatment of depression
- Describe therapeutic properties and review research

EXISTING THERAPY

- > The pathophysiology of MDD remains unc
- > The monoamine hypothesis is the most wid accepted model that has been proposed
- \blacktriangleright The development of agents for the treatmer depression has largely followed this hypoth explanation of observed efficacy
- > Mechanism refinement in newer antidepres helped improve tolerability
- Side effect burden remains a concern with antidepressants including SSRIs, which are widely prescribed class
- \succ Up to 43% of patients with MDD have stop an antidepressant due to side effects
- > Onset of clinical effect and response can reweeks to months

Drug Development

- > A general lack of novel agents for the treat depression can be attributed to:
 - Costly late-stage trial failures
 - Limited understanding of the biological mental disorders
- \triangleright Esketamine was approved for use in 2019 as an adjunct therapy in treatment-resistant depression

Psilocybin in the Treatment of Depression Ben Hoelscher, PharmD Candidate Ronald Worthington, PhD

Efficacy

nmon criencing an ts for the y stagnant t in the	 Around two-thirds of patients init not have remission in symptoms Relapse is seen within 6-12 mont Number needed to treat (NNT) is NNT is conventionally used v Therapeutic alliance and experience of antidepressant R These non-specific factors are response observed in antidepressant Estimated NNT of placebo-control Mild-to-moderate: 16, Severe
psilocybin	PSIL
	 Compound found in a variety of Psychoactive compounds psilocy
	psilocin were identified in 1958 and 7Clinical studies in the 60's and 7
clear	 produced by psilocybin Psychedelic use became associat to the Vietnam war
	 Oregon is developing a framewo Qualified facilitators with approp
ssants has	P Binds with high affinity as an ag
e the most	 receptor and lacks affinity for the Agonism at the 5-HT2A receptor neurotrophic factor (BDNF) and
pped taking	Cortical layer V
equire	-1 Glutamate NMDAR release
ment of	AMPAR
l basis of	€ BDNF

Ž

its initially treated with an antidepressant will

months in approximately 50% of patients NT) is a common metric of drug efficacy used with the control condition being placebo l expectancy are present in the placebo sant RCTs for the treatment of MDD ors are responsible for an estimated 60-80% of tidepressant RCTs

controlled antidepressant trials by severity: Severe: 11, Very-severe: 4

SILOCYBIN

History

ety of mushrooms

silocybin and the major active metabolite

1958 at Sandoz laboratories then marketed

and 70's found an altered state of consciousness

sociated with cultural rebellion and opposition

Current Legislation


Psilocin/

LSD/DMT

nework for medical psilocybin administration appropriate training will deliver therapy **Properties**

an agonist or partial agonist at the 5-HT2A for the dopamine D2 receptor

ceptor is thought to increase brain-derived) and produce the "dream-like" effect



SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE SCHOOL OF PHARMACY

RECENT RESEARCH

Proposed Mechanism of Action (MOA)

➢ fMRI has revealed decreased integrity of the default mode network (DMN) during psilocybin administration > Increases in cortical neuroplasticity with long-term changes in network functionality have been observed

Safety

Psilocybin can be safely administered under medical supervision in patients with no history of or predisposition to psychotic disorders. No dependency observed.

Outcomes

> Available research has suggested rapid and long-lasting positive effects of psilocybin in the treatment of depression when administered in a supportive environment

Trial of Psilocybin versus Escitalopram for Depression Randomized double-blind phase 2 clinical trial (n=59) Psilocybin arm: 25 mg psiliocybin 3 weeks apart and 6 weeks of daily placebo (n=30)

Escitalopram arm: 6 weeks of once daily escitalopram and 1 mg psilocybin 3 weeks apart (n=29)

Primary efficacy outcome: change from baseline in the QIDS-SR 16: Psilocybin -8.0 \pm 1.0 points, escitalopram -6.0 + 1.0 (95% CI, -5.0 to 0.9)

Secondary outcomes included measures of anxiety, anhedonia, experiential avoidance, sexual dysfunction, emotional intensity, and well-being among others > All secondary outcomes favored psilocybin

CONCLUSION

> Any agents with potential for long-lasting efficacy and an acceptable safety profile should be investigated in MDD Safety and regulatory issues will need to be addressed through thorough screening and protocol implementation

> Approval of psilocybin in the treatment of depression would introduce an entirely novel MOA to psychiatry > Psilocybin research has produced novel outcome measures not traditionally seen in antidepressant RCTs

> Adoption of a treatment modality requiring a behavioral component such as psilocybin could result in a shift of the existing mental health landscape